Skip to content
Clinical Trials – home
BelgiumBack to Belgium

Clinical trials in Kessel-Lo – page 164

1 979 clinical trials in Kessel-Lo, Belgium. Every trial is listed in the EU Clinical Trials Register and updated daily.

Kessel-Lo at a glance
1 979
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

1 979 trials in Kessel-Lo

Open in trial search

Study on the Effects of Durvalumab, Oleclumab, and Chemotherapy in Patients with Luminal B Breast Cancer

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years
  • Substances:Cyclophosphamide
  • Sponsor:Institut Jules Bordet

Cystic fibrosis

Not recruiting

Long-term safety and efficacy study of elexacaftor/tezacaftor/ivacaftor treatment in people with cystic fibrosis who have non-F508del genetic mutations

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years
  • Substances:Elexacaftor
  • Sponsor:Vertex Pharmaceuticals Inc.

Study on the Effects of Latozinemab for Patients with Frontotemporal Dementia Due to Progranulin Gene Mutations

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Latozinemab
  • Sponsor:Alector LLC
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Olaparib
  • Sponsor:Belgian Society Of Medical Oncology

Breast cancer+2

Not recruiting

Study of Durvalumab, Olaparib, and Fulvestrant for Patients with ER-Positive, HER2-Negative Advanced Breast Cancer with Specific Genetic Alterations

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Durvalumab
  • Sponsor:Unicancer

Study on Talazoparib and Enzalutamide for Patients with Metastatic Castration-Resistant Prostate Cancer

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Enzalutamide
  • Sponsor:Pfizer Inc.

Study of Tucidinostat and Nivolumab for Patients with Advanced Melanoma Not Treated with PD-1 or PD-L1 Inhibitors

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Nivolumab
  • Sponsor:Huyabio International LLC

Breast cancer

Not recruiting

Study on Amcenestrant Alone and with Drug Combination for Postmenopausal Women with Estrogen Receptor-Positive Advanced Breast Cancer

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Abemaciclib
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Study Comparing ONC-392 and Docetaxel for Patients with Metastatic Non-Small Cell Lung Cancer After PD-1/PD-L1 Inhibitor Treatment

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Docetaxel
  • Sponsor:Oncoc4 Inc.

Study on the Effects of Buspirone Hydrochloride for Patients with Weak or Absent Esophageal Motility

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Buspirone Hydrochloride
  • Sponsor:UZ Leuven

Study on Imatinib and Chemotherapy Combination for Children with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years
  • Substances:Crisantaspase
  • Sponsor:Universita Degli Studi Di Milano Bicocca

Asthma

Not recruiting

Study on Reducing Asthma Medication with Tezepelumab in Patients Aged 12 to 80 with Severe Asthma

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Tezepelumab
  • Sponsor:AstraZeneca AB

Other cities in Belgium

The busiest research cities in the country

All 164 cities in Belgium

Clinical research in Kessel-Lo

What the registry says about research in the country

01 Gastroenterology Research

Innovative clinical trials focusing on proton pump inhibitor (PPI) deprescribing strategies for patients with chronic usage patterns. This research explores alternative treatment approaches for common digestive conditions.

  • Functional Dyspepsia Management
  • Gastroesophageal Reflux Treatment
  • Heartburn Control Methods

The study evaluates various therapeutic approaches, including on-demand medication and alginate-based alternatives, to optimize treatment protocols for patients with digestive disorders.

02 Primary Care Innovation

Research examining optimal medication reduction strategies in primary care settings, with a focus on improving long-term patient outcomes and reducing unnecessary medication use.

  • Medication Optimization
  • Patient-Centered Care
  • Therapeutic Alternative Assessment

This initiative aims to establish evidence-based guidelines for discontinuing long-term medications when they may no longer be clinically indicated.

03 Treatment Comparison Studies

Comparative research evaluating the effectiveness of different deprescribing approaches in managing common gastrointestinal conditions.

  • Medication Withdrawal Strategies
  • Alternative Treatment Methods
  • Clinical Outcome Assessment

The research compares traditional dose reduction methods with newer therapeutic strategies to determine optimal treatment pathways.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.